NovaSeq 6000 Sequencing System is by far our most powerful instrument, designed to adapt to your needs.
Kits & Reagents
P1 reagents are now available for NextSeq 1000/NextSeq 2000 Systems, offering added flexibility to meet your project's needs
Selection & Planning Tools
Software & Informatics Products
DRAGEN v3.9 release now available with multi-cloud support, accuracy improvements and more
Improved Q30 score, support for UMIs, extended shelf life, and support for Illumina DNA PCR-Free Library Prep
Illumina and the San Diego Zoo Wildlife Alliance try to preserve the species with the help of genomic data
All Investor Information
All Support Tools
Product Support Services
Multiomics methods can better connect genotype to phenotype
Cancer Research Products
Microbial Genomics Research
Learn about methods for SARS-CoV-2 surveillance, including requirements, workflow, and analysis
Microbial Genomics Products
Array-based SNP genotyping platforms have low genotype error rates compared to genotyping-by-sequencing
Explore the advantages of NGS for analysis of gene expression, gene regulation, and methylation
Complex Disease Research Products
See what is possible through the latest advances in high-throughput sequencing technology
Prof. Dr. Bernd Eiben discusses his experience with VeriSeq NIPT Solution v2
Reproductive Health Products
Illumina supports the release of a landmark consensus on whole-genome sequencing in the diagnosis of genetic diseases in newborns
Genetic Health Products
The MiSeqDx instrument is the first FDA-cleared in vitro diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDx applications include FDA-cleared and FDA-approved assays for cystic fibrosis testing, colorectal cancer evaluation, and NGS-based assay development.
FDA-cleared next-generation sequencing panels for detection of causative and clinically relevant variants for cystic fibrosis.